Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Bacopa Monnieri | Phenibut | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 300-450 mg/day of standardized extract (24-55% bacosides, typically Bacognize or Synapsa brands) | 250-750 mg as needed, maximum 1-2 times per week (for educational context — carries significant dependence risk) |
| Timing | With a fat-containing meal to improve absorption of fat-soluble bacosides. Morning or evening — some users report mild sedation. Minimum 8-12 weeks for full cognitive effects. | On an empty stomach (food significantly reduces absorption). Onset 2-4 hours. Effects last 4-8 hours with residual effects up to 24 hours. Half-life approximately 5.3 hours. |
| Cycle Duration | Ongoing; benefits accumulate over months. No strict cycling required. | STRICTLY intermittent use only — maximum 1-2 times per week. NEVER use daily for more than 1 week. Tolerance develops within days, leading to dose escalation and dependence. |
| Evidence Level | strong_human | moderate_human |
Active triterpenoid saponins (bacosides A and B) provide multifaceted neuroprotection: inhibition of acetylcholinesterase (AChE) and activation of choline acetyltransferase (ChAT) to enhance cholinergic neurotransmission; upregulation of tryptophan hydroxylase and serotonin transporter expression to modulate serotonergic tone; antioxidant neuroprotection via induction of superoxide dismutase and glutathione peroxidase; and reduction of beta-amyloid aggregation. Additionally enhances GABA signaling through GABA-A receptor subunit upregulation and glutamate decarboxylase activation.
300-450 mg/day of standardized extract (24-55% bacosides, typically Bacognize or Synapsa brands)
With a fat-containing meal to improve absorption of fat-soluble bacosides. Morning or evening — some users report mild sedation. Minimum 8-12 weeks for full cognitive effects.
Ongoing; benefits accumulate over months. No strict cycling required.
Beta-phenyl derivative of GABA that crosses the blood-brain barrier (unlike GABA itself) due to the addition of a phenyl ring. Acts as a full agonist at GABA-B receptors with 30-68x lower affinity than baclofen, requiring correspondingly higher doses. Also binds to and blocks alpha-2-delta subunit-containing voltage-dependent calcium channels (VDCCs), making it a gabapentinoid similar to gabapentin and pregabalin. At low concentrations, mildly increases dopamine levels in the brain, providing stimulatory and nootropic effects alongside anxiolysis. Weak agonist activity at GABA-A receptors at higher doses.
250-750 mg as needed, maximum 1-2 times per week (for educational context — carries significant dependence risk)
On an empty stomach (food significantly reduces absorption). Onset 2-4 hours. Effects last 4-8 hours with residual effects up to 24 hours. Half-life approximately 5.3 hours.
STRICTLY intermittent use only — maximum 1-2 times per week. NEVER use daily for more than 1 week. Tolerance develops within days, leading to dose escalation and dependence.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →